Exagen, Inc.
Vista, CA, United States
ACR Bio
Geoffrey Stephens is an experienced Ph.D. scientific executive with 19 years working in all aspects of large and small biotechnology companies. Dr. Stephens is currently the Associate VP of R&D at Exagen Inc, an autoimmune diagnostics company located in Vista, CA. Exagen aims to aid patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions.
His current interest includes using sophisticated data mining for uncovering unique patterns in data to support development of novel tests to aid in the diagnosis of rheumatological diseases.
Previously, Dr. Stephens led teams discovering biologics across all stages of development while he was at AstraZeneca (AZ)/MedImmune. During his tenure there, he identified several targets that were ultimately developed to various stages in the AZ pipeline for the treatment of autoimmune/inflammatory diseases. Dr. Stephens also played an integral role in the development and eventual FDA approval of Benralizamab (Fasenra), an anti-IL-5Ra specific antibody for the treatment of asthma. More recently, he was the Head of Process Development at Tessa Therapeutics developing CD30-CAR-T cell therapies for the treatment of Hodgkin and non-Hodgkin lymphoma. Dr. Stephens did his post-doctoral training at the NIH/NIAID in the Laboratory of Cellular Immunology under the mentorship of Dr. Ethan Shevach.
Disclosure information not submitted.
Saturday, November 12, 2022
1:00 PM – 3:00 PM Eastern Time
Monday, November 14, 2022
4:30 PM – 4:40 PM Eastern Time
